Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Cincinnati, Ohio Clear all
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
View directory record Official record
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

NCT04546724
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
VLA1553, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
4,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
44
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 25, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

NCT04504188
View directory record Official record
Conditions
Cardiomyopathies, Heart Failure
Interventions
Heart Rate Monitor Enhanced Treatment Optimization
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Cincinnati, Ohio • Kingwood, Texas • McKinney, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 25, 2026, 9:15 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

NCT04641442
View directory record Official record
Conditions
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Interventions
MAS825, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
4
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 25, 2026, 9:15 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

NCT07455383
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Cullman, Alabama • Los Angeles, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 25, 2026, 9:15 AM EDT
Completed No phase listed Observational

Pharmacogenetic Morphine Spine Study

NCT01839461
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Flu Vaccine Doses in Children

NCT01164553
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 35 Months
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

NCT04636437
View directory record Official record
Conditions
HIV Infections
Interventions
Doravirine 100 Mg, Integrase strand transfer inhibitors, Tenofovir alafenamide/emtricitabine, tenofovir disproxil fumarate/emtricitabine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

NCT01455896
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, ITCA placebo
Drug · Other
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
4,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Hayward, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

NCT04142242
View directory record Official record
Conditions
Meningococcal Infection (Healthy Volunteers)
Interventions
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
59 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
33
States / cities
Chandler, Arizona • San Diego, California • Waterbury, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 25, 2026, 9:15 AM EDT
Recruiting Phase 3 Interventional

E-Mindfulness Approaches for Living After Breast Cancer

NCT06748222
View directory record Official record
Conditions
Breast Cancer, Depression
Interventions
Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 50 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
362
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 304 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

NCT02451137
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
407
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional

Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis

NCT05660772
View directory record Official record
Conditions
Knee Osteoarthritis, Osteo Arthritis Knee
Interventions
Microfragmented Adipose Tissue, Corticosteroid
Device · Drug
Lead sponsor
Lipogems International spa
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Encinitas, California • Redwood City, California • Gulf Breeze, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 25, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

NCT02110069
View directory record Official record
Conditions
Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
Interventions
Vincristine, Sirolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 31 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 25, 2026, 9:15 AM EDT
Completed No phase listed Observational

Results of Ocular Compression and Suture Release in Trabeculectomy and Combined Surgery

NCT00327405
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2006 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

NCT04759131
View directory record Official record
Conditions
Hemophilia A
Interventions
efanesoctocog alfa (BIVV001)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

NCT01150045
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
826
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 25, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

NCT03896295
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

NCT02683239
View directory record Official record
Conditions
Osteoarthritis of the Knee or Hip
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 25, 2026, 9:15 AM EDT
Active, not recruiting Not applicable Interventional

The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis Study

NCT04943172
View directory record Official record
Conditions
Deep Venous Insufficiency (Diagnosis)
Interventions
Hancock-Jaffe bioprosthetic venous valve (VenoValve®)
Device
Lead sponsor
Hancock Jaffe Laboratiores, Inc
Network
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Jul 25, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

NCT00483977
View directory record Official record
Conditions
Osteoarthritis
Interventions
Oxycodone, Placebo, PF-000592379
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
21
States / cities
Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of ALT-801 in the Treatment of Obesity

NCT05295875
View directory record Official record
Conditions
Obesity/Overweight
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
31
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jul 25, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

NCT01414920
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
80
States / cities
Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Jul 25, 2026, 9:15 AM EDT